Dr. Gradishar on the Role of Neratinib in the Treatment of HER2+ Breast Cancer

William J. Gradishar, MD
Published: Friday, Oct 13, 2017



William J. Gradishar, MD, interim chief of Hematology and Oncology in the Department of Medicine, Betsy Bramsen Professorship of Breast Oncology, professor of Medicine, Hematology and Oncology, Northwestern University Feinberg School of Medicine, discusses the role of neratinib (Nerlynx) in the treatment of patients with HER2-positive breast cancer.

In the early stage, one of the challenges is integrating pertuzumab (Perjeta) and neratinib (Nerlynx) into the neoadjuvant setting.

Neratinib may be considered in high-risk patients after treatment with the combination of pertuzumab and trastuzumab (Herceptin).
 


William J. Gradishar, MD, interim chief of Hematology and Oncology in the Department of Medicine, Betsy Bramsen Professorship of Breast Oncology, professor of Medicine, Hematology and Oncology, Northwestern University Feinberg School of Medicine, discusses the role of neratinib (Nerlynx) in the treatment of patients with HER2-positive breast cancer.

In the early stage, one of the challenges is integrating pertuzumab (Perjeta) and neratinib (Nerlynx) into the neoadjuvant setting.

Neratinib may be considered in high-risk patients after treatment with the combination of pertuzumab and trastuzumab (Herceptin).
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast CancerJul 31, 20181.0
Community Practice Connections™: Medical Crossfire®: Translating Lessons Learned with PARP Inhibition to the Treatment of Breast Cancer—Expert Exchanges on Novel Strategies to Personalize CareAug 29, 20181.5
Publication Bottom Border
Border Publication
x